001     131790
005     20240229105013.0
024 7 _ |a 10.1038/nature25169
|2 doi
024 7 _ |a pmid:29258295
|2 pmid
024 7 _ |a 0028-0836
|2 ISSN
024 7 _ |a 1476-4687
|2 ISSN
024 7 _ |a altmetric:30719581
|2 altmetric
037 _ _ |a DKFZ-2018-00087
041 _ _ |a eng
082 _ _ |a 070
100 1 _ |a Mack, Stephen C
|b 0
245 _ _ |a Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
260 _ _ |a London [u.a.]
|c 2018
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1677760963_19615
|2 PUB:(DE-HGF)
|x Letter
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Genomic sequencing has driven precision-based oncology therapy; however, the genetic drivers of many malignancies remain unknown or non-targetable, so alternative approaches to the identification of therapeutic leads are necessary. Ependymomas are chemotherapy-resistant brain tumours, which, despite genomic sequencing, lack effective molecular targets. Intracranial ependymomas are segregated on the basis of anatomical location (supratentorial region or posterior fossa) and further divided into distinct molecular subgroups that reflect differences in the age of onset, gender predominance and response to therapy. The most common and aggressive subgroup, posterior fossa ependymoma group A (PF-EPN-A), occurs in young children and appears to lack recurrent somatic mutations. Conversely, posterior fossa ependymoma group B (PF-EPN-B) tumours display frequent large-scale copy number gains and losses but have favourable clinical outcomes. More than 70% of supratentorial ependymomas are defined by highly recurrent gene fusions in the NF-κB subunit gene RELA (ST-EPN-RELA), and a smaller number involve fusion of the gene encoding the transcriptional activator YAP1 (ST-EPN-YAP1). Subependymomas, a distinct histologic variant, can also be found within the supratetorial and posterior fossa compartments, and account for the majority of tumours in the molecular subgroups ST-EPN-SE and PF-EPN-SE. Here we describe mapping of active chromatin landscapes in 42 primary ependymomas in two non-overlapping primary ependymoma cohorts, with the goal of identifying essential super-enhancer-associated genes on which tumour cells depend. Enhancer regions revealed putative oncogenes, molecular targets and pathways; inhibition of these targets with small molecule inhibitors or short hairpin RNA diminished the proliferation of patient-derived neurospheres and increased survival in mouse models of ependymomas. Through profiling of transcriptional enhancers, our study provides a framework for target and drug discovery in other cancers that lack known genetic drivers and are therefore difficult to treat.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Pajtler, Kristian
|0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
|b 1
|e First author
700 1 _ |a Chavez, Lukas
|0 P:(DE-He78)082dd3179733e3e716a58eb90f418a78
|b 2
|e First author
700 1 _ |a Okonechnikov, Konstantin
|0 P:(DE-He78)34b3639de467b2c700920d7cbc3d2110
|b 3
700 1 _ |a Bertrand, Kelsey C
|b 4
700 1 _ |a Wang, Xiuxing
|b 5
700 1 _ |a Erkek, Serap
|0 P:(DE-He78)df8660bc5aba525f7fb6dba4aac15c1c
|b 6
700 1 _ |a Federation, Alexander
|b 7
700 1 _ |a Song, Anne
|b 8
700 1 _ |a Lee, Christine
|b 9
700 1 _ |a Wang, Xin
|b 10
700 1 _ |a McDonald, Laura
|b 11
700 1 _ |a Morrow, James J
|b 12
700 1 _ |a Saiakhova, Alina
|b 13
700 1 _ |a Sin-Chan, Patrick
|b 14
700 1 _ |a Wu, Qiulian
|b 15
700 1 _ |a Michaelraj, Kulandaimanuvel Antony
|b 16
700 1 _ |a Miller, Tyler E
|b 17
700 1 _ |a Hubert, Christopher G
|b 18
700 1 _ |a Ryzhova, Marina
|b 19
700 1 _ |a Garzia, Livia
|b 20
700 1 _ |a Donovan, Laura
|b 21
700 1 _ |a Dombrowski, Stephen
|b 22
700 1 _ |a Factor, Daniel C
|b 23
700 1 _ |a Luu, Betty
|b 24
700 1 _ |a Valentim, Claudia L L
|b 25
700 1 _ |a Gimple, Ryan C
|b 26
700 1 _ |a Morton, Andrew
|b 27
700 1 _ |a Kim, Leo
|b 28
700 1 _ |a Prager, Briana C
|b 29
700 1 _ |a Lee, John J Y
|b 30
700 1 _ |a Wu, Xiaochong
|b 31
700 1 _ |a Zuccaro, Jennifer
|b 32
700 1 _ |a Thompson, Yuan
|b 33
700 1 _ |a Holgado, Borja L
|b 34
700 1 _ |a Reimand, Jüri
|b 35
700 1 _ |a Ke, Susan Q
|b 36
700 1 _ |a Tropper, Adam
|b 37
700 1 _ |a Lai, Sisi
|b 38
700 1 _ |a Vijayarajah, Senthuran
|b 39
700 1 _ |a Doan, Sylvia
|b 40
700 1 _ |a Mahadev, Vaidehi
|b 41
700 1 _ |a Miñan, Ana Fernandez
|b 42
700 1 _ |a Gröbner, Susanne
|0 P:(DE-He78)932918ed0e8d8790a81235528019a8e0
|b 43
700 1 _ |a Lienhard, Matthias
|b 44
700 1 _ |a Zapatka, Marc
|0 P:(DE-He78)1beba8f953e7ae7e96e8d3e9a48f10f7
|b 45
700 1 _ |a Huang, Zhiqin
|0 P:(DE-He78)c16f26d78779ca1c53b6939e7a5ce788
|b 46
700 1 _ |a Aldape, Kenneth D
|b 47
700 1 _ |a Carcaboso, Angel M
|b 48
700 1 _ |a Houghton, Peter J
|b 49
700 1 _ |a Keir, Stephen T
|b 50
700 1 _ |a Milde, Till
|0 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
|b 51
700 1 _ |a Witt, Hendrik
|0 P:(DE-He78)046fd145f1008f83f6236580727bbc0f
|b 52
700 1 _ |a Li, Yan
|b 53
700 1 _ |a Li, Chao-Jun
|b 54
700 1 _ |a Bian, Xiu-Wu
|b 55
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 56
700 1 _ |a Scott, Ian
|b 57
700 1 _ |a Singh, Sheila K
|b 58
700 1 _ |a Huang, Annie
|b 59
700 1 _ |a Dirks, Peter B
|b 60
700 1 _ |a Bouffet, Eric
|b 61
700 1 _ |a Bradner, James E
|b 62
700 1 _ |a Ramaswamy, Vijay
|b 63
700 1 _ |a Jabado, Nada
|b 64
700 1 _ |a Rutka, James T
|b 65
700 1 _ |a Northcott, Paul A
|b 66
700 1 _ |a Lupien, Mathieu
|b 67
700 1 _ |a Lichter, Peter
|0 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
|b 68
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 69
700 1 _ |a Scacheri, Peter C
|b 70
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 71
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 72
|e Last author
700 1 _ |a Taylor, Michael D
|b 73
700 1 _ |a Rich, Jeremy N
|b 74
773 _ _ |a 10.1038/nature25169
|g Vol. 553, no. 7686, p. 101 - 105
|0 PERI:(DE-600)1413423-8
|n 7686
|p 101 - 105
|t Nature
|v 553
|y 2018
|x 1476-4687
909 C O |p VDB
|o oai:inrepo02.dkfz.de:131790
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)082dd3179733e3e716a58eb90f418a78
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)34b3639de467b2c700920d7cbc3d2110
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)df8660bc5aba525f7fb6dba4aac15c1c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 43
|6 P:(DE-He78)932918ed0e8d8790a81235528019a8e0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 45
|6 P:(DE-He78)1beba8f953e7ae7e96e8d3e9a48f10f7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 46
|6 P:(DE-He78)c16f26d78779ca1c53b6939e7a5ce788
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 51
|6 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 52
|6 P:(DE-He78)046fd145f1008f83f6236580727bbc0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 56
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 68
|6 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 69
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 71
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 72
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NATURE : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b NATURE : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 1
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l B060 Molekulare Genetik
|x 2
920 1 _ |0 I:(DE-He78)G340-20160331
|k G340
|l KKE Pädiatrische Onkologie
|x 3
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a I:(DE-He78)G340-20160331
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21